<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042885</url>
  </required_header>
  <id_info>
    <org_study_id>314-12-401</org_study_id>
    <secondary_id>2013-001249-15</secondary_id>
    <nct_id>NCT02042885</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer</brief_title>
  <official_title>A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Novel Products GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Novel Products GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the tolerability profile of OPB-111001 and to&#xD;
      determine the most suitable dose of OPB-111001 in patients with advanced cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose / Recommended Phase 2 dose; Tolerability</measure>
    <time_frame>after 2 or 6 weeks depending on study part; continously</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters for OPB-111001 and its metabolites</measure>
    <time_frame>repeatedly until end of study (average of 3 months assumed)</time_frame>
    <description>Frequent sampling during Cycle 1 to 3, D1 only from Cycle 4 onwards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of antitumor activity as defined by Response Evaluation Criteria in Solid Tumours (RECIST)</measure>
    <time_frame>repeatedly every 8th week until end of study (average of 3 months assumed)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA) response in patients with prostate cancer</measure>
    <time_frame>repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer antigen 125 (CA 125) response in patients with ovarian cancer</measure>
    <time_frame>repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>At end of study (after average of 3 months assumed)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Salivary Gland Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Cervix</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>1: Regimen A Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1: OPB-111001, orally, once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Regimen A Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2: OPB-111001, orally, once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Regimen B Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3: OPB-111001, orally, 2 - 3 times per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Regimen B Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4: OPB-111001, orally, 2 - 3 times per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPB-111001</intervention_name>
    <arm_group_label>1: Regimen A Escalation</arm_group_label>
    <arm_group_label>2: Regimen A Extension</arm_group_label>
    <arm_group_label>3: Regimen B Escalation</arm_group_label>
    <arm_group_label>4: Regimen B Extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  Patients with prostate cancer that is recurrent or did not respond to previous hormone&#xD;
             therapy and/or who have exhausted standard treatment options.&#xD;
&#xD;
        For the dose escalation parts only:&#xD;
&#xD;
        Patients who have exhausted standard treatment options with recurrent or refractory cancer&#xD;
        (ovarian cancer, cervical squamous cell carcinoma, breast cancer, salivary gland cancer,&#xD;
        endometrial cancer)&#xD;
&#xD;
          -  Histologically or cytologically documented diagnosis of cancer&#xD;
&#xD;
          -  Measurable disease according to RECIST Version 1.1 or for prostate cancer also&#xD;
             evaluable disease according to Prostate Cancer Working Group 2 (PCWG2) eligibility&#xD;
             criteria or for ovarian cancer also evaluable disease (non-measurable) according to&#xD;
             Gynaecologic Cancer Intergroup (GCIG) criteria&#xD;
&#xD;
          -  Absolute neutrophil count ≥1.5 (1500/mm3) and platelets ≥100 × 109/L (without platelet&#xD;
             transfusion within the last 4 weeks before first study drug administration), and&#xD;
             haemoglobin ≥9 g/dL at Screening&#xD;
&#xD;
          -  Alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of&#xD;
             normal (ULN), Total bilirubin ≤1.5 × ULN (exception: patients with liver metastasis&#xD;
             are allowed to have aspartate aminotransferase ≤5 × ULN and alanine aminotransferase&#xD;
             ≤5 × ULN) at screening&#xD;
&#xD;
          -  Albumin ≥26 g/L at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent prior treatment-related toxicity of Grade 2 or higher. Exception: any&#xD;
             toxicity that is in the view of the investigator not a clinically significant safety&#xD;
             risk for Investigational medicinal product (IMP) administration.&#xD;
&#xD;
          -  Previous treatment with cytotoxic chemotherapy or other anticancer therapy within 4&#xD;
             weeks before the first dosing with study drug (at least 6 weeks for mitoxantrone,&#xD;
             nitrosurea, and bicalutamide).&#xD;
&#xD;
          -  Treatment with systemic glucocorticosteroids of more than a 2 mg dexamethasone&#xD;
             equivalent per day or in cases of treatment with ≤2 mg dexamethasone equivalent per&#xD;
             day:&#xD;
&#xD;
               1. Dosing was changed within 6 weeks before Screening or&#xD;
&#xD;
               2. The patient's cancer is responding to glucocorticosteroid intake&#xD;
&#xD;
          -  Radiation therapy within 4 weeks prior to the first dosing with IMP.&#xD;
&#xD;
          -  Treatment with a systemic IMP in a clinical trial within 28 days before the Screening&#xD;
             Visit.&#xD;
&#xD;
          -  Current or past history of clinically significant gastrointestinal disease or major&#xD;
             gastrointestinal surgery, malabsorption syndrome, or other conditions that could&#xD;
             interfere with enteral absorption.&#xD;
&#xD;
          -  Concurrent clinically significant unrelated systemic illness (e.g., serious infection)&#xD;
             or significant pulmonary, hepatic, or other organ dysfunction that would compromise&#xD;
             the patient's ability to tolerate study treatment or would likely interfere with study&#xD;
             procedures or results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johann De Bono, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Institute of Cancer Research, Royal Marsden NHS Foundation Trust London United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Blagden, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIHR/Wellcome Trust Imperial CRF, Imperial College Healthcare NHS Trust, Imperial Center for Translational and Experimental Medicine (L-Block), Hammersmith Hospital London, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Institute of Cancer Research, Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London, Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIHR/Wellcome Trust Imperial CRF/Imperial College Healthcare NHS Trust, Imperial Centre for Translational and Experimental Medicine (L-Block), Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

